Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Albireo
Pharma
Mirum gets 2nd indication for blockbuster hopeful Livmarli
FDA has OK'd Mirum’s Livmarli to treat the rare liver disease PFIC. The nod comes on top of another for Livmarli to treat Alagille syndrome in 2021.
Kevin Dunleavy
Mar 13, 2024 6:20pm
Mirum ponies up $445M for 2 Travere liver disease drugs
Jul 18, 2023 8:00am
After Albireo buyout, Ipsen's Bylvay picks up new use
Jun 13, 2023 2:02pm
How a sudden withdrawal led to M&A bidding war for Albireo
Jan 24, 2023 11:36am
Ipsen CEO 'not at all afraid' of Big Pharma in rare diseases
Jan 18, 2023 10:55am
Ipsen pays $952M to acquire Albireo and liver disease med Bylvay
Jan 9, 2023 10:05am
